Ticker

NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changes NRx conducted a meeting with leadership of the FDA Office of Generic Drugs in which support was voiced for the potential approval of the Abbreviated New Drug Application within the current review cycle. Ketamine is identified as medically necessary by the US Department of…

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic…

Nanobiotix (NASDAQ: NBTX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Insider and Institutional Ownership 38.8% of Nanobiotix shares

Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret.

WILMINGTON, Del., April 13, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company's first Chief Commercial Officer. As NRx looks forward to the anticipated approval of its Abbreviated New Drug Application for their…